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AbstrAct
Levels of prostaglandin E2 and the prostaglandin-
endoperoxide synthase-2 (PTGS2, or COX-2) 
increase in actively progressing periodontal 
lesions, but decrease in chronic disease. We 
hypothesized that chronic inflammation is associ-
ated with altered DNA methylation levels within 
the PTGS2 promoter, with effects on COX-2 
mRNA expression. PTGS2 promoter methylation 
levels from periodontally inflamed gingival biop-
sies showed a 5.06-fold increase as compared with 
non-inflamed samples (p = 0.03), and the odds of 
methylation in a CpG site in the inflamed gingival 
group is 4.46 times higher than in the same site in 
the non-inflamed group (p = 0.016). The level of 
methylation at -458 bp was inversely associated 
with transcriptional levels of PTGS2 (RT-PCR) 
(p = 0.01). Analysis of the data suggests that, in 
chronically inflamed tissues, there is a hypermeth-
ylation pattern of the PTGS2 promoter in association 
with a lower level of PTGS2 transcription, consistent 
with a dampening of COX-2 expression in chronic 
periodontitis. These findings suggest that the chronic 
persistence of the biofilm and inflammation may be 
associated with epigenetic changes in local tissues at 
the biofilm-gingival interface.
KEY WOrDs: DNA methylation, PTGS2, CpG 
islands, periodontitis.
INtrODUctION
t he production of prostaglandin E2 (PGE2) has been associated with periodontal inflammation (Goodson et al., 1974; Noguchi and Ishikawa, 
2007). In periodontitis, increased levels of gingival crevicular fluid (GCF) 
PGE2 have been predictive of longitudinal periodontal attachment loss 
(Offenbacher et al., 1986), and associated with the clinical signs of bleeding 
on probing (Zhong et al., 2007), both of which would suggest that increased 
PGE2 expression is associated with progressive lesions (Champagne et al., 
2003). The biosynthesis of PGE2 and other prostanoids is tightly coupled to 
the inducible expression of COX-2, and the transcriptional control of COX-2 
levels appears to be the key regulatory gate for modulating tissue PGE2 levels 
(Noguchi et al., 2000). Although levels of PGE2 increase during certain stages 
of disease progression, little is known regarding the regulation of local PGE2 
synthesis, in which some down-regulation must be needed to prevent a contin-
ued and ever-expansive loss of connective tissue. This homeostasis in chronic 
inflammation in the omnipresence of a microbial burden is probably due to 
the establishment of what has been referred as a “metastable” equilibrium 
(Feinberg and Tycko, 2004). This metastable equilibrium arises as the pres-
ence of a chronic inflammatory stimulus creates a new “set-point”, in which 
higher levels of inflammatory mediators are tolerated or down-regulated by 
some compensatory molecular mechanism(s) that prevent unrestricted tissue 
destruction and serve to dampen the uncontrolled inflammatory response.
Analysis of data in the literature provides some evidence of this down-
regulatory mechanism. In a community study (Zhong et al., 2007), it was 
reported that the level of GCF PGE2 is negatively associated with attachment 
loss (as a marker of total history of disease activity), indicating that the 
greater the cumulative historical tissue damage, the lower the GCF-PGE2 
level. Presumably, this is a result of a site-specific history of an episode of 
progression with increased attachment loss and elevations of local GCF PGE2 
levels that eventually become dormant with lowered levels of PGE2.
Recently, we have found that certain periodontal bacteria can induce 
epigenetic alterations in host tissues, such as gene-specific methylation of 
CpG sequences (Bobetsis et al., 2007). In eukaryotes, DNA methylation 
occurs almost exclusively at the 5′ end of cytosine within the CpG 
dinucleotide context (Bird and Wolffe, 1999). It has been generally 
accepted that an increase of methylation in the gene promoter region is 
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related to the decrease of gene expression, though exceptions 
have been identified (Kelavkar et al., 2007).
In this study, we sought to investigate the potential alteration 
in the DNA methylation pattern of the PTGS2 (COX2) gene 
promoter and its effect on the transcriptional control of COX-2. 
We also sought to identify potential feedback mechanisms 
that might lead to the suppression of PGE2 synthesis following 
periods of disease activity.
MAtErIALs & MEtHODs
Participants and tissue specimens
In total, 16 participants, aged between 18 and 65 yrs, provided 
written informed consent and were enrolled into this study, which 
was approved by the Institutional Review Board of the University 
of North Carolina at Chapel Hill. Exclusion criteria included: 
(1) the use of either antibiotics or non-steroidal anti-inflammatory 
drugs within 1 mo prior to scheduled surgery; and (2) medical treat-
ment for other diseases 3 mos prior to recruitment. Measurements 
included probing depths, clinical attachment level, and bleeding on 
probing at 6 sites per tooth. One interproximal gingival site was 
biopsied from each participant. Ten gingival biopsies were removed 
during routine periodontal flap surgeries from participants clini-
cally diagnosed with chronic adult periodontitis. Those biopsied 
tissues were from sites with probing depths of 5 mm or more, 
bleeding on probing, and radiographic evidence of localized bone 
loss. These tissues are referred to as ‘inflamed’ in the data presenta-
tion. Non-inflamed tissues were collected from participants who 
were periodontally healthy or had localized mild gingivitis at non-
study sites. Six non-inflamed gingival biopsies were removed from 
participants who were undergoing crown extension surgery at sites 
with probing depth measurements of 4 mm or less at all 4 inter-
proximal probing sites and no bleeding on probing. Upon removal, 
gingival tissues were incubated with RNAlater® (Applied 
Biosystems/Ambion, Austin, TX, USA) overnight at 4°C, decanted 
and transferred to a freezer at -80°C for storage.
DNA Preparation and sodium bisulfite Modification
Genomic DNA was isolated from gingival biopsies by the use of 
a DNeasy Tissue Kit (Qiagen Inc., Valencia, CA, USA). A 2-μg 
quantity of genomic DNA from each sample was treated with 
sodium bisulfite according to the method recommended (Grunau 
et al., 2001).
bisulfite specific Pcr, cloning, and sequencing
The promoter sequence of PTGS2 (Appleby et al., 1994) was ana-
lyzed with MethPrimer software (Li and Dahiya, 2002). Two CpG 
islands encompassing -541 bp and -216 bp were identified. Sodium-
bisulfite treated genomic DNA was amplified with primers that are 
specific to the CpG islands within the PTGS2 promoter. Primer 
sequences and PCR conditions are provided in the APPENDIX. A 
334-bp PCR product including those 2 CpG islands was purified 
through electrophoresis, and the gel-purified PCR product was then 
cloned into a pGEM-T Easy vector (Promega, Madison, WI, USA). 
Colonies showing positive PCR fragment insertion were selected, 
and the insert was amplified with standard Sp6 and T7 primers 
(Promega) listed in the APPENDIX (including PCR conditions). 
PCR products from 4 to 7 clones for each individual gingival 
sample were sequenced at the UNC-CH genomic analysis facility.
rNA Isolation and real-time Pcr
Total RNA was isolated from RNAlater®-treated gingival tissues 
with the use of an RNeasy Mini Kit (Qiagen). cDNA was then syn-
thesized from 1 μg of total RNA with the Omniscript Kit (Qiagen) 
by random decamer primers (Applied Biosystems/Ambion). Real-
time PCR was performed with 1 μL synthesized cDNA, TaqMan 
Universal PCR mix, and 20X on-demand primers (Applied 
Biosystems, Foster City, CA, USA) specific for the PTGS2 gene, in 
a 7000 Sequence Detection System apparatus (Applied Biosystems). 
Amplification of 18s rRNA from each gingival sample was included 
as internal control. The relative quantity of PTGS2 mRNA was 
calculated against 18S rRNA values (Livak and Schmittgen, 2001). 
Two samples, one from inflamed and one from non-inflamed gingi-
val groups, did not provide enough RNA for analyses, and therefore 
were excluded from the quantitative RT-PCR study.
statistical Analysis
Two-sample independent t tests were applied for the statistical 
analysis of clinical data and mRNA expression levels. We used the 
Mann-Whitney/Wilcoxon two-sample test (SAS v9.2) to compare 
overall percent methylation of each gingival sample between the 2 
gingival groups. We used a generalized linear mixed model 
(GLMM) to estimate the odds ratio describing the relationship 
between methylation and inflamed vs. non-inflamed groups, condi-
tional on CpG site and gingival tissue sample. Specifically, a three-
level logistic regression model (Kim et al., 2006), with fixed effect 
for group and random effects for samples and sites within samples, 
was used. A 95% confidence interval for the odds ratio was con-
structed such that the observed difference between groups was 
assessed with respect to the variation between gingival tissue sam-
ples. We applied linear regression analysis to test for the signifi-
cance of slope to evaluate the association between the percentage 
of methylation at a specific CpG dinucleotide (-458 bp) within the 
PTGS2 promoter region and the PTGS2 transcriptional level. We 
used chi-square approximation to test gender difference between 




There were no significant differences in age and gender between 
the two groups (Table). As expected, there were differences in 
mean probing depth, clinical attachment loss, and the presence 
of bone loss at inflamed sites as compared with sites in control 
individuals without inflammation.
Methylation status of the cpG-rich  
PTGS2 Promoter region
The overall methylation of the studied PTGS2 promoter region 
(-541 bp ~ -216 bp) in chronically inflamed gingival tissues was 
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5.06-fold higher than the methylation level exhibited in non-
inflamed gingival tissues when the methylation levels of 
individual gingival tissue in both groups were compared 
[4.3% (1.8%, 8.5%) vs. 0.85% (0.7%, 1.3%), respectively, 
shown as median and interquartile range (IQR), p = 0.03] 
(Fig. 1). There are 23 CpG dinucleotides (Fig. 2A) present in 
2 CpG islands (shaded area, Fig. 2B) within the upstream 
sequences of PTGS2 (-831 bp to +69 bp, Fig. 2B). Several 
transcription factor binding sequences (cis-elements), such as 
NF-κB, AP-2, and Sp-1 (Fig. 2A), were also identified within 
these CpG-rich regions. Therefore, we analyzed the methyla-
tion state of all 23 CpG sites within those regions to compare 
methylation levels between the two gingival sample groups. 
The individual clonal bisulfite sequencing map for the 16 
participants appears in the APPENDIX Fig. It can be seen 
that the increased methylation shown in inflamed tissues 
extends over almost all of the 23 potential methylation sites 
analyzed (Fig. 2C). However, this diffuse methylation pattern 
was absent from the non-inflamed samples, in which meth-
ylation could be detected at only 3 CpG sites. In addition, the 
odds of methylation at a CpG site from a sample in the 
inflamed gingival group was 4.46 times higher (95% CI: 
1.38, 14.35) than the odds of methylation at the same CpG 
site from a sample in the non-inflamed gingival group (p = 
0.016), as estimated by the GLMM.
Interestingly, the most heavily methylated site in both 
gingival tissue groups occurred at what we are designating as 
“site 8” (-458 bp, Fig. 2C), a CpG dinucleotide that is physi-
cally close to an NF-κB binding site (Fig. 2A). The methyla-
tion level of that particular CpG site was 23.5% in inflamed 
and 20.6% in non-inflamed gingival tissues, and higher than 
the methylation levels of other CpG dinucleotides in both 
groups (Fig. 2C).
cpG Methylation status as related  
to PTGS2 mrNA Expression Level
The mRNA level of PTGS2 in inflamed gingival samples, as 
determined by real-time PCR, was lower than the level in the 
non-inflamed group, although the difference was not signifi-
cant (p = 0.36, Fig. 3A). We then plotted the percentage meth-
ylation level of “site 8” against the mRNA expression level of 
each individual sample. Samples from both gingival tissue 
groups are shown on this plot to demonstrate the association 
between methylation status and mRNA expression. The overall 
regression analysis pooling all clinical samples shows a statis-
tically significant negative association between percentage of 
methylation of the CpG site at -458 bp and PTGS2 mRNA 
expression (p = 0.01, Fig. 3B).
DIscUssION
Although aging and environmental exposures can affect 
global genome methylation, new evidence indicates that 
some promoter methylation sites can be targeted by specific 
toxins, nutrient deficiencies, and infectious stimuli to modify 
methylation levels (Vanselow et al., 2006; Wasson et al., 
2006). In this investigation, we report that chronically 
inflamed periodontal tissues exhibited an increased (5.06-
fold) generalized methylation of the CpG-rich region of the 
PTGS2 promoter, as compared with non-inflamed periodon-
tal tissues. In a previous study with a mouse model of 
Campylobacter rectus infection, we identified a hypermeth-
ylated Igf2 P0 promoter region, suggesting, for the first time, 
that infection with an oral pathogen can lead to epigenetic 
modifications (Bobetsis et al., 2007). The association 
between infection and alteration of DNA methylation is also 
supported by another study in an in vitro infection model 
(Yao et al., 2006), which reported that the promoter region of 
table. Clinical Parameters of Study Participants
Clinical Measurements Inflamed (n = 10) Non-inflamed (n = 6)
Mean age (yrs) 45.8 ± 7.4 44.2 ± 15.6
Gender (Male/Female) 5/5 1/5
Mean probing depth (mm)a   6.2 ± 0.6   2.5 ± 0.8
Mean clinical attachment  
  loss (mm)b
  3.8 ± 1.1   1.6 ± 1.1
Alveolar bone loss Yes No
a Statistically significant difference by t test (p = 0.00001). Value reflects 
mean interproximal probing depth aggregated over 4 interproximal 
sites at the biopsy region.
b Statistically significant difference by t test (p = 0.01). Value reflects mean 
interproximal clinical attachment loss aggregated over 4 interproximal 
sites at the biopsy region.
Figure 1. PTGS2 promoter region (-541 bp ~ -216 bp) DNA methyla-
tion levels for both groups of gingival samples. The methylation level 
in chronic inflamed periodontitis samples [4.3% (1.8%, 8.5%)] was 
significantly higher than that in non-inflamed samples [0.85% (0.7%, 
1.3%), *p = 0.03], as determined by the Mann-Whitney/Wilcoxon 
two-sample test. Box plot shows the median (center line in box), 25% 
quartile (bottom line in box), 75% quartile (top line in box), maximum 
(plus error bar), and minimum (minus error bar).
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Figure 3. Transcriptional levels of PTGS2, determined by quantitative 
RT-PCR, from the inflamed and non-inflamed gingival samples. (A) mRNA 
expression of PTGS2 in the inflamed gingival group showed lower, yet 
non-statistically different (p = 0.36), levels as compared with non-inflamed 
gingival tissues. (B) The PTGS2 mRNA expression level of individual 
samples from both groups is inversely related to its methylation level of 
“site 8” CpG dinucleotides. Regression analysis indicates statistical 
significance (p = 0.01).
Figure 2. Methylation level of individual CpG site within the promoter 
region of PTGS2. (A) Genomic sequence of PTGS2 promoter region 
ranging from -541 bp to -216 bp is presented. Sites for potential tran-
scriptional factor binding are underlined. 23 CpG potential methyla-
tion sites are present in this region and marked with “*”. The 8th CpG 
(-458 bp) site is also indicated in a larger font size. (B) Diagrammatic 
representation of the PTGS2 gene promoter from -831 bp to +69 bp 
is shown. The shaded areas indicate CpG islands in this promoter 
region. The vertical bars underneath represent CpG potential methyla-
tion sites, with 23 sites within the CpG island in parentheses. (C) The 
methylation level of each individual CpG site within the identified CpG 
islands from inflamed periodontitis biopsies is compared with that in 
the non-inflamed samples. “Site 8” is marked with “#”.
hMLH1 from a gastric cell line was hypermethylated by per-
sistent Helicobacter pylori infection. Therefore, our findings 
are consistent with the concept that infections at mucosal 
surfaces can modify the epigenetic status of the tissues in a 
gene-specific manner. The role of inflammation in modulat-
ing methylation status, either by altering the density of cells 
at local sites of inflammatory infiltration, or by modifying 
the methylation status of existing cells, cannot be determined 
from these experiments. Furthermore, the intra-clonal differ-
ences of methylation status within the same gingival tissue 
sample (e.g., Appendix Fig.; participant 8 had 10 methylated 
sites in one clone, but none in 4 other clones) may reflect the 
epigenetic impact imposed by infection/inflammation on dif-
ferent cell types present in the biopsy samples.
The increase in methylation in chronic disease was associ-
ated with a metastable steady-state level of PTGS2 mRNA 
expression that was lower than that seen in non-inflamed par-
ticipants with shallow sites. This finding is consistent with the 
report (Zhong et al., 2007) that shows lower PGE2 levels in 
deeper sites. It has been suggested (Beck et al., 1997) that most 
of the periodontal disease progression that occurs within par-
ticipants likely involves shallow sites rather than deep sites. In 
this context, the chronic state of deep pockets reflects a histori-
cal episode of disease activity and a re-instatement of a new 
steady-state equilibrium, resulting in a metastable shift in 
COX-2 expression.
The site-specific methylation of the CpG dinucleotide at site 
-458 bp (“site 8”), which is located 12 bp upstream of an NF-κB 
binding site, was higher in both gingival groups. Since NF-κB 
activation enhances PTGS2 expression (Newton et al., 1997), 
the observed increase in methylation at this specific site 
may impair NF-κB activation. It has been reported (Kelavkar 
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et al., 2007) that transcription can be critically affected by the 
methylation status of specific or “key” CpG sites within a regu-
latory region. In the present study, the methylated cytosine of 
this CpG dinucleotide, just upstream of the NF-κB binding site, 
may possibly either directly exclude the binding by this tran-
scriptional activator or condense local chromatin structure by 
recruiting methyl CpG binding proteins (Bird and Wolffe, 1999; 
Vanselow et al., 2006).
One limitation of this report is the relatively small number of 
participants studied. Relationships between methylation status 
and clinical status are tenuous and should be confirmed in larger 
studies. However, this study provides the first evidence and proof-
of-principle that epigenetic modifications of local tissues may 
occur in periodontal disease. Additional studies will be needed to 
understand whether epigenetic changes also occur in gingivitis or 
in other mucosal pathologies. Although we demonstrated that 
promoter methylation is linked to decreased mRNA expression, 
we do not have direct evidence that this is associated with altered 
levels of COX-2 protein expression or levels of PGE2 within the 
tissue. However, once the PTGS2 mRNA is translated into pro-
tein, the enzyme is unstable, having a short biological half-life 
(Perkins and Kniss, 1997). COX-2 does not exist in a zymogen 
form or as a pre-existing mRNA pool. Thus, the transcription of 
PTGS2 mRNA directly results in the synthesis of inducible 
COX-2 and appears to be the key regulatory gate for modulating 
tissue COX-2 activity.
Our working model of how epigenetic modification may affect 
periodontal status is based upon: (1) how changes in DNA meth-
ylation patterns alter gene expression profiles; (2) the fact that epi-
genetic changes are not readily reversible and are retained following 
cell division, creating a sustained change in gene expression and 
tissue phenotype that would persist, even following the reduction in 
the inflammatory infiltrate; (3) the fact that epigenetic alterations 
may induce tissue tolerance to the chronic stress imposed by the 
biofilm; and (4) the fact that epigenetic alterations may influence 
wound healing and the dynamics of biofilm emergence. This sug-
gests that epigenetic modifications may result in long-lived altera-
tions in the metastable state of the local periodontal tissues.
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